Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AC Immune (ACIU) Operating Income: 2015-2025

Historic Operating Income for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to -$20.2 million.

  • AC Immune's Operating Income fell 340.87% to -$20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.4 million, marking a year-over-year decrease of 106.89%. This contributed to the annual value of -$59.8 million for FY2024, which is 1.10% up from last year.
  • Per AC Immune's latest filing, its Operating Income stood at -$20.2 million for Q3 2025, which was up 13.71% from -$23.4 million recorded in Q2 2025.
  • In the past 5 years, AC Immune's Operating Income ranged from a high of $8.4 million in Q3 2024 and a low of -$24.7 million during Q4 2021.
  • For the 3-year period, AC Immune's Operating Income averaged around -$16.7 million, with its median value being -$20.2 million (2025).
  • The largest annual percentage gain for AC Immune's Operating Income in the last 5 years was 147.92% (2024), contrasted with its biggest fall of 432.39% (2024).
  • Over the past 5 years, AC Immune's Operating Income (Quarterly) stood at -$24.7 million in 2021, then grew by 21.47% to -$19.4 million in 2022, then soared by 79.43% to -$4.0 million in 2023, then slumped by 432.39% to -$21.3 million in 2024, then plummeted by 340.87% to -$20.2 million in 2025.
  • Its Operating Income stands at -$20.2 million for Q3 2025, versus -$23.4 million for Q2 2025 and -$21.5 million for Q1 2025.